Practice Point 2.2.1:
Safe achievement of lower HbA1c targets (e.g., <6.5% or <7.0%) may be facilitated by CGM or SMBG and by selection of antihyperglycemic agents that are not associated with hypoglycemia.

Please click here to view the 'Glycemic monitoring' flow chart.

Practice Point 2.2.2:
CGM metrics such as time in range and time in hypoglycemia may be considered as alternatives to HbA1c for defining glycemic targets in some patients.

Practice Point 2.1.5:
For patients with type 2 diabetes (T2D) and CKD who choose not to do daily glycemic monitoring by CGM or SMBG, antihyperglycemic agents that pose a lower risk of hypoglycemia are preferred and should be administered in doses that are appropriate for the level of eGFR.

Please click here to view the 'Glycemic monitoring' flow chart.